Quick Summary
- Sustained and Improving Efficacy: The ICOTYDE Icotrokinra Results from the one-year Phase 3 trials showed that skin clearance didn’t just last—it improved. In the ICONIC-ADVANCE 1 study, complete skin clearance (PASI 100) rose from 41% at Week 24 to 49% at Week 52.
- Transformative for Adolescents: Nearly 60% of adolescent patients (ages 12+) achieved completely clear skin after one year of treatment. With 86% reaching near-clear skin (PASI 90), these ICOTYDE Icotrokinra Results establish the once-daily pill as a powerful new systemic option for younger populations.
- Consistent Safety Profile: Throughout the 52-week ICONIC-LEAD and ADVANCE studies, no new safety signals were identified. The treatment maintained a favorable safety profile with infection rates remaining lower than those observed in competitors like deucravacitinib during head-to-head assessments.
ICOTYDE Icotrokinra Results from the latest Phase 3 clinical trials mark a significant shift in the treatment landscape for moderate-to-severe plaque psoriasis. Johnson & Johnson recently presented long-term 52-week data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, confirming that this once-daily oral peptide provides lasting skin clearance and a favorable safety profile for both adults and adolescents.
Breakthrough ICOTYDE Icotrokinra Results in Phase 3 Trials
The one-year data, derived from the ICONIC-ADVANCE 1 and 2 studies, evaluated the efficacy of icotrokinra against both a placebo and the active comparator, deucravacitinib. The findings were notable: the percentage of patients achieving PASI 100 (completely clear skin) actually increased between Week 24 and Week 52.
In the ADVANCE 1 study, complete clearance rates rose from 41% to 49%, while ADVANCE 2 saw an increase from 33% to 48%. These ICOTYDE Icotrokinra Results demonstrate that the medication’s efficacy is not only maintained but potentially improves with long-term, consistent dosing.
Detailed Efficacy Data: A Closer Look at the Numbers
The following table summarizes the primary endpoints and the significant skin clearance achieved across the ICONIC clinical program.
| Study Group | Metric | Week 24 Result | Week 52 Result |
| ICONIC-ADVANCE 1 (Adults) | PASI 100 (Clear Skin) | 41% | 49% |
| ICONIC-ADVANCE 2 (Adults) | PASI 100 (Clear Skin) | 33% | 48% |
| ICONIC-LEAD (Adolescents) | PASI 100 (Clear Skin) | — | 57% |
| ICONIC-LEAD (Adolescents) | PASI 90 (Near Clear) | — | 86% |
| ICONIC-LEAD (Adolescents) | IGA 0 (Total Clearance) | — | 61% |
Read More: Johnson & Johnson’s Icotrokinra Shows Significant Skin Clearance in Difficult-to-Treat Psoriasis
Safety and Efficacy in Adolescents
The ICONIC-LEAD study focused on a vulnerable demographic: patients aged 12 and older. The ICOTYDE Icotrokinra Results for this group were particularly impressive. Nearly 60% of adolescents achieved completely clear skin at the one-year mark, with 92% of those who reached PASI 90 at Week 24 maintaining that response through Week 52.
BiotechReality JobFinder
- Role Information As a Regulatory Specialist at GSK, you will work within the Renewals CMC Team. This team plays a […]
- Role Information As a Medical Device Associate Consultant at IQVIA, you will step into a world where data, technology, and […]
- Role Information As a Manufacturing Quality Assurance Engineer at Agilent, you will be at the forefront of ensuring that our […]
- Role Information As the Product Manager for Immunoassay (IA), you will be the primary driver of growth for Beckman Coulter’s […]
- Role Information As a Quality Specialist at their Schwaikheim site, you will be a key driver in ensuring that our […]
- Role Information As a Clinical Trial Associate (CTA) within our Functional Service Provider (FSP) division, you will play a vital […]
Future Regulatory Outlook: Expanding the Reach of ICOTYDE
Following the landmark ICOTYDE Icotrokinra Results presented at the 2026 AAD Annual Meeting, the regulatory trajectory for this first-in-class oral peptide is moving into a high-growth phase. Having already secured FDA approval in March 2026 for moderate-to-severe plaque psoriasis in both adults and adolescents, Johnson & Johnson is now focused on global expansion and label extensions.
Global Market Access and Pending Approvals
The success of the ICONIC clinical program has paved the way for submissions to international health authorities. The focus is currently on the European market, where a decision from the European Medicines Agency (EMA) is anticipated later in 2026.
| Regulatory Agency | Current Status | Expected Timeline |
| U.S. FDA | Approved (March 18, 2026) | Commercial Launch Underway |
| EMA (Europe) | Under Review (Filed Sept 2025) | Decision Expected Q3/Q4 2026 |
| PMDA (Japan) | Phase 3 Trials Ongoing | Filing Anticipated 2027 |
| NMPA (China) | Clinical Development | Filing Anticipated 2027+ |
Read More: Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis
Pipeline Expansion: Beyond Plaque Psoriasis
The ICOTYDE Icotrokinra Results in skin clearance have validated the IL-23 receptor as a potent target for oral peptides. Consequently, J&J is aggressively pursuing label extensions for other inflammatory and immune-mediated (I&I) conditions.
- Psoriatic Arthritis (PsA): Two pivotal Phase 3 trials, ICONIC-PsA 1 and 2, are currently evaluating icotrokinra in biologic-naive and biologic-experienced patients. Positive data here could lead to a supplemental New Drug Application (sNDA) by late 2027.
- Inflammatory Bowel Disease (IBD): Following promising Phase 2b results, the ICONIC-UC (Ulcerative Colitis) and ICONIC-CD (Crohn’s Disease) Phase 3 programs are active. These represent significant market opportunities, as oral options for IBD remain a high unmet need.
- Head-to-Head Superiority: The ICONIC-ASCEND study is uniquely positioned to demonstrate the superiority of this oral pill against the injectable biologic Stelara. If successful, this could shift the regulatory “standard of care” definition for first-line systemic therapy.
J&J’s ICOTYDE Icotrokinra Results Confirm Long-Term Skin Clearance in Psoriasis Patients
Johnson & Johnson has announced breakthrough one-year data for ICOTYDE (icotrokinra), demonstrating that the once-daily oral peptide maintains high rates of skin clearance and a […]
EBGLYSS Durable Efficacy: Lilly Reports Landmark 4-Year Results for Atopic Dermatitis
Quick Summary Exceptional Long-Term Efficacy: After four years of continuous treatment, 94% of patients achieved significant skin improvement (EASI-75), and 75% reached near-complete skin clearance […]
Pfizer and Valneva Announce Strong Efficacy for Lyme Disease Vaccine Candidate
Topline results from the Phase 3 VALOR study demonstrate that the Lyme disease vaccine candidate (PF-07307405) is safe, well-tolerated, and effective for adults and children. […]
Strategic Commercial Positioning
With the expiration of patents for major biologics like Stelara, J&J is positioning ICOTYDE as the next-generation successor. Analysts suggest that the combination of “biologic-like” efficacy and the convenience of a once-daily pill could allow icotrokinra to capture a dominant share of the oral psoriasis market, currently contested by TYK2 inhibitors.
The favorable ICOTYDE Icotrokinra Results in the adolescent population (12+) provide a distinct regulatory advantage, as many competing oral systemics are currently restricted to adult use only.
